TBD Therapeutics Inc. develops breakthrough solution for the treatment of NEUROPATHIC PAIN
Neuropathic Pain- Main Causes
▶️ PHYSICAL INJURY
Car accidents, Broken bones, Spine injuries, Sports, Medical Procedures, Soldiers injuries.
▶️ CANCER
Chemotherapy, Radiation, Tumors
▶️ DIABETES
Nerve damage
▶️ ALCOHOISM
Nerve damage
▶️ WOMEN RELATED CONDITIONS
Women organs diseases
▶️ ELDERLY POPULATION
Age-related health conditions
▶️ CENTRAL NERVOUS SYSTEM DISORDERS
Stroke, Parkinson's Diseases, Multiple Sclerosis
▶️ AUTOIMMUNE DISEASES
Rheumatoid Arthritis, Psoriasis, Lupus, HIV , Shingles
Neuropathic Pain - The Solution
As an efficacious, safe, non-narcotic drug, our technology will:
✔ Improve patients’ compliance with continuous treatment.
✔ Improve patients’ ability to work and their economical situation.
✔ Improve patient’s social life.
✔ Improve patient’s family members’ quality of life.
✔ Reduce side effects in patients who have chronic pain with comorbidities.
✔ Patients are less likely to develop tolerance with chronic use.
✔ Keep patients away from all types of medical facilities, from consuming more medications- Reducing drastically healthcare system costs.
✔ Better treatment will improve health, Quality of Life and vitality, leading to much greater Longevity.
NEUROPATHIC PAIN - MARKET POTENTIAL
-
The global Neuropathic Pain market account for over US$ 6,313.4 Mn in terms of value in 2019 and is estimated to reach around US$ 25 billion by the end of 2027.
-
Rising incidences of cancer, diabetes and growing geriatric population is expected to drive growth of the global neuropathic pain market.
-
The North America region held a significant position in the global neuropathic pain market in 2019, accounting for over 35.9% share in terms of value, followed by Europe.